PreClinical CRO dedicated to your NonClinical projects

you are here : DRUG EVALUATION SERVICES

NEWS

Animal models for Parkinson Disease?

We just came back from the last edition of “World Congress on Parkinson’s Disease and Related Disorders” that took place last week on Geneva, Switzerland. This International congress brought together leading clinical and pre-clinical experts, scientists from University


New PAH results with the Monocrotaline model

Pulmonary Arterial Hypertension (PAH) is an orphan disease, incurable that remains highly lethal despite recent advanced medical treatment.


Syncrosome at the Neuroconnection Symposium

Syncrosome invites you to visit us at Neuroconnection in Marseille the 1st and 2nd July. In the framework of the European project NeuroRescue, this symposium is an European event around technological innovation and private-public partnerships in NEUROSCIENCES and AGEING.


Animal models of Diabete?

Diabetes is a chronic metabolic disorder, caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin. The WHO estimates that 346 million people worldwide have diabetes.



DRUG EVALUATION SERVICES:

How can I find the information I am looking for?


To have a overview of our services go to the homepage.

More detailled information in the sub pages of "drug evaluation services":
- Drug efficacy
- In Vivo pharmacokinetics
- Safety assessment

We can provide you with a combinated form of these studies for example
- Efficacy and early safety in the same experiment.
- Efficacy and Pharmacokinetics: advanced PK/PD.
- Safety and Pharmacokinetics: DMPK.

The main objective of combined studies is to improve scientific relevance by analysing the safety and pharmacokinetics aspects of your compounds on the same species which has been used for efficacy.

Combined studies allow for a reduction in the number of animal subjects used.
The final benefit of combined studies is to optimize the use of your budget!